For decades, the World Health Organization (WHO) has recommended systemic use of antimonial drugs for treatment of cutaneous leishmaniasis (CL). However, global responses to these treatments are heterogeneous and vary between different species of Leishmania. For example, although administration of 20mg Sb 5+/ kg/day is suggested for 20 days, the treatment regime must follow regional guidelines when available. In 2010, a committee of leishmaniasis specialists updated the global recommendations published in 1990. The 2010 committee concluded that leishmaniasis treatment was characterized by limited therapeutic options and use of toxic medications. However, CL is not a life-threatening condition, and serious complications of CL, including progression to the mucosal form, are infrequent. Therefore, treatments for CL should not induce life-threatening complications; local treatments are safer and are therefore preferred, despite minimal evidence for their effi cacy. However, a risk-benefi t analysis of systemic therapy should be conducted for patients with complicated or multiple lesions that are very large, or that are located such that they impede local therapy (for example, disfi guring lesions on the face). Therefore, systemic therapy may be indicated after evaluating possible contraindications, provided that adverse effects of such therapies are monitored (1) (2) . Based on the results of recent studies, the Pan American Health Organization (PAHO) updated the WHO recommendations in 2013 and adapted them to both the known characteristics of leishmaniasis and to current health service provision. In addition, the PAHO recommendations emphasize the need to incorporate evidence from national control programs, and to consider variables such as the species of Leishmania, clinical characteristics, and patient access to health services. Ideally, recommendations should be based on controlled clinical trials evaluating the availability of therapeutic alternatives; in particular, trials should be conducted to assess local treatments that currently have low-quality evidence and weak recommendations for use, but which may be effective. The PAHO recommended intralesional treatment (IL) for patients with a single lesion and contraindications to systemic treatment (patients with kidney, liver, and heart diseases, who are >50 years of age). IL treatment is contraindicated for patients with immunosuppression and lesions that are >3cm in diameter, or that are localized in periarticular areas such as the head. In addition, IL treatment should include 1-5 intradermal infi ltrations of 1-5mL of meglumine antimoniate (MA) every 3-7 days. The required volume is calculated by the following formula: larger diameter of the lesion in mm × smaller diameter × 0.008mL (3) .
In Brazil, systemic therapy with 10-20mg Sb 5+ /kg/day, to a maximum limit of 3 ampoules daily for 20 days, is the fi rst choice for CL treatment (4) . Between 2007 and 2013, 159,301 cases of CL were observed in Brazil; the 885 (0.5%) associated deaths resulted from either CL or other causes (annual average deaths associated with CL, 126) (5) . (3) and the MS (4) (6) (7) (8) (9) (10) .
In order to provide new evidence for the effi cacy of IL treatment with MA, the technique used at the INI/FIOCRUZ is described as follows (Figure 1 ): 1) apply skin antiseptic around the lesion; 2) infi ltrate with MA; if the patient experiences pain, administer an injection of 1% lidocaine; 3) use a long medium-caliber needle (for example, 30mm × 0.8mm) to facilitate infi ltration; 4) use a syringe with a luer-lock connection because high resistance occurs when infi ltrating the lesion, leading to abrupt needle undocking with drug extravasation. It may be necessary to use the palm to depress the plunger; 5) insert the needle into the skin at a 45° angle, 0.5-1.0cm distant from the edge of the lesion, and into the subcutaneous tissue beneath each quadrant, toward the center of the lesion; ensure siphoning before application to avoid injecting intravascularly; 6) inject the volume needed to infi ltrate the base of the lesion by raising it and producing intumescence (generally 5-20mL). It is possible to infi ltrate small lesions from 1 or 2 points. 7) During the infi ltration, jet extravasation of the drug may occur through the surface of the lesion. Therefore, goggles, a face mask, gloves, and an apron are recommended.
Lesions on bone protuberances, such as the pre-tibial region, usually require a lesser volume compared to other lesions. Lesions of the same size, but which are located in regions such as the abdomen or neck require a greater volume. Therefore, calculating the volume of MA to be injected (3) based only on the area of the lesion, is not always useful. In practice, the necessary volume of MA can be injected until the infi ltrated area is intumesced and acquires a consistency that is similar to a cheek full of air upon palpation. The maximum daily dose of MA recommended via intramuscular (IM) or intravenous (IV) is 15mL in Brazil. However, given the positive therapeutic results obtained with IL volumes > 5mL, with an effi ciency of 83.3% and without signifi cant systemic toxicity (8) , subcutaneous infi ltration of greater MA volumes appear to be appropriate. Additionally, we do not contraindicate infi ltrating lesions >3cm or those that are located in periarticular areas or in the head; however, the anatomical peculiarities of the face, as well as the presence of vessels, nerves, and noble structures must be considered (3) (4) (6) (7) (8) .
A favorable therapeutic response after 1-3 applications is expected. If total epithelialization of the lesions is not observed by approximately 15 days after the fi rst application, a second application is indicated. If total epithelialization is not observed by approximately day 30, a third and last application is indicated. The patient should then be reexamined every 15 days, and progression towards epithelialization should be observed for as many as 120 days. In the months following epithelialization, crusts, desquamation, infi ltration, and erythema disappear successively, and the lesion is healed (7) (8) (9) (10) . Therefore, short intervals of 3-7 days between treatments (3) are unnecessary. Furthermore, treatment can be reinitiated using the same protocol if continuous progression to complete healing does not occur.
Adverse clinical, laboratory, and electrocardiographic effects mild or moderate may be observed; however, these effects do not indicate treatment interruption. Local or systemic cutaneous reactions to IM MA should be considered in relation to IL treatment, with regard to the risk of intense local reactions (9) .
Treatment of CL with IL MA is simple, effi cient, and safe. Furthermore, this treatment protocol can be used in basic healthcare settings. However, current standard practices include restrictions or recommendations that differ from the protocols used at the INI over the last 30 years. Therefore, IL treatment should be queried and investigated in other centers, particularly in basic healthcare settings. We have described our technique in detail, with the intention that this treatment may be replicated in other health centers, thereby contributing to generation of evidence for treatment effi cacy.
The broad suggestion of IL treatment for CL under the same conditions of clinical follow-up and monitoring of adverse effects available for the standard systemic treatment may reduce morbidity and mortality related to the therapy for this disease in Brazil.
